ABBV
FY2026 Q1 · Calendar Q2 2026
AbbVie Inc.
AbbVie's Q1 FY2026 results reinforce the post-Humira transition thesis: Skyrizi and Rinvoq are delivering double-digit growth and gaining market share across psoriatic disease, IBD, and emerging dermatology indications, more than offsetting ongoing biosimilar erosion of Humira. With a raised full-year adjusted EPS guidance range of $14.08-$14.28, a deep pipeline spanning obesity (ABBV-295), oncology (Temab-A, PD-1/VEGF bispecifics), and neuroscience (tavapadon, VYALEV), and significant manufacturing capacity investments, management signaled confidence in sustained growth. The stock's +3.1% earnings-day move and +7.2% subsequent drift suggest the market is endorsing the beat-and-raise narrative.
EPS surprise+2.3%
Market move+3.1%
